Apotex Inc.

Apotex Inc. is a Canadian-based global pharmaceutical company, recognized as the largest producer of generic drugs in Canada. Founded in 1974, its core mission is to improve everyday access to affordable, high-quality, and innovative medicines and health products for millions of people worldwide. The company's headquarters are located in Toronto, Ontario, Canada.

Apotex's extensive portfolio includes over 300 generic pharmaceuticals available in approximately 4,000 dosages and formats, addressing a wide range of health conditions such as cancer, diabetes, high cholesterol, glaucoma, infections, and blood pressure. Beyond generic medications, the company is actively involved in research and development, the manufacturing of fine chemicals, non-prescription and private-label medicines, and disposable plastics for medical use. Apotex also has a significant presence in the biosimilar market and serves over 115 countries globally, with key operations in Canada, the United States, Mexico, and India.

In March 2026, Jeff Watson was appointed President and CEO, marking his return to the leadership role he previously held from 2018 to 2023. This change followed Allan Oberman's decision to step down as CEO and resume a board member position. Apotex, a portfolio company of SK Capital Partners since its acquisition in April 2023, has been in the news recently for several key developments. In May 2026, Health Canada approved Apo-Semaglutide Injection, a generic equivalent of Ozempic®, making Apotex the first Canadian-based pharmaceutical company to achieve this. The company also announced a strategic transaction in April 2026 with Cumberland Pharmaceuticals to integrate their U.S. branded businesses and received Health Canada approval for DENOZA™, a Denosumab Biosimilar. Furthermore, there are ongoing reports from early 2026 about a potential initial public offering (IPO) in the first half of the year, aiming to raise between $750 million and $1 billion, though SK Capital Partners is expected to retain control.

Latest updates

Apotex Secures Ozempic Generic Approval, Challenging Novo Nordisk's Dominance in Canada

Event summary

  • Apotex Inc. received Health Canada approval for Apo-Semaglutide Injection, a generic equivalent of Novo Nordisk's Ozempic®.
  • Apotex is the first Canadian pharmaceutical company to gain approval for an Ozempic generic.
  • The approved product will be available in both 2 mg/pen and 4 mg/pen formats, mirroring Ozempic’s existing SKUs.
  • The drug is indicated for the treatment of type 2 diabetes in adults, in combination with diet and exercise.
  • Apotex collaborated with Orbicular Pharmaceutical Technologies in the development of Apo-Semaglutide Injection.

The big picture

This approval marks a significant challenge to Novo Nordisk's dominance in the Canadian diabetes market, particularly given the global demand and high prices associated with Ozempic. The entry of a generic competitor will likely increase access to this crucial medication for Canadian patients and put pressure on healthcare costs. Apotex’s success hinges on its ability to navigate regulatory hurdles and effectively compete with Novo Nordisk’s established brand recognition and distribution network.

What we're watching

Market Penetration
The speed at which Apo-Semaglutide Injection is adopted by Canadian physicians and patients will determine the initial impact on Novo Nordisk's sales and market share.
Pricing Dynamics
How aggressively Apotex prices Apo-Semaglutide Injection will be a key indicator of its strategy to gain market share and the potential for downward pressure on Ozempic pricing.
Legal Challenges
Novo Nordisk may pursue legal challenges to protect its patents and market exclusivity, potentially delaying or limiting Apotex’s ability to fully capitalize on the approval.
CID: 911